Measurement of circulating tumor cells in squamous cell carcinoma of the head and neck and patient outcomes

• T. M. Morgan ^[1] ; X. Wang ^[3] ; X. Qian ^[3] ; J. M. Switchenko ^[3] ; S. Nie ^[3] ; K. R. Patel ^[2] ; R. J. Cassidy ^[1] ; D. M. Shin ^[3] ; J. J. Beitler ^[1]
  1. [1] Emory University

     Emory University

     Estados Unidos

     
  2. [2] Yale University

     Yale University

     Town of New Haven, Estados Unidos

     
  3. [3] Winship Cancer Institute. Atlanta, USA

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 3, 2019, págs. 342-347
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objectives We report the outcomes of patients with squamous cell carcinoma of the head and neck (HNSCC) whose circulating tumor cells (CTCs) were quantified using surface-enhanced Raman scattering (SERS) nanotechnology.

    Methods SERS tagged with EGF was used to directly measure targeted CTCs. Patient charts were retrospectively reviewed. An optimal cut point for CTCs in 7.5 ml of peripheral blood predictive of for distant metastasis-free survival (DMFS) was identified by maximizing the log-rank statistic. An ROC analysis was also performed.

    Results Of 82 patients, 13 experienced metastatic progression. The optimal cut point for DMFS was 675 CTCs (p = 0.047). For those with distant recurrence (n = 13) versus those without distant recurrence (n = 69), the CTC cut point which results in the largest combined sensitivity and specificity values is also 675 (sensitivity = 69%, specificity = 68%).

    Conclusion Liquid biopsy techniques in HNSCC show promise as a means of identifying patients at greater risk of disease progression.